Arylisoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors

Details for Australian Patent Application No. 2007207053 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Buettelmann, Bernd; Knust, Henner; Han, Bo; Thomas, Andrew

Agent Spruson & Ferguson

Pub. Number AU-B-2007207053

PCT Pub. Number WO2007/082806

Priority 06100426.3 17.01.06 EP

Filing date 8 January 2007

Wipo publication date 26 July 2007

Acceptance publication date 24 May 2012

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/437 (2006.01)

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

7 August 2008 PCT application entered the National Phase

  PCT publication WO2007/082806 Priority application(s): WO2007/082806

24 May 2012 Application Accepted

  Published as AU-B-2007207053

20 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007207055-Thiazoles as 11 beta-HSD1 inhibitors

2007207052-CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors